Acute myelogenous leukemia (AML) cells were also sensitised to treatment when miRNA-142-3p levels are increased, via repression of high mobility box group 1 (HMGB1), an autophagic promoter, and P-glycoprotein, a drug efflux pump [140]. The gene discussed is HMGB1; the disease is acute myeloid leukemia.